Ambrosia, Syneron move toward clinic with nine-digit series B rounds: Finance Report

Amid a short holiday week with few financings, Ambrosia drew a $100 million series B crossover round that will allow the biotech to advance a pipeline of oral therapies for obesity and other metabolic conditions, while China-based Syneron closed its $150 million series B to develop macrocyclic peptides.

Boulder, Colo.-based Ambrosia Biosciences Inc. said its products have differentiated pharmacology and are designed to be either standalone or part of combinations. The new cash will support clinical development of its therapy targeting GLP-1R, while other programs aimed at GIPR and amylin are moving toward human testing...